NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
NEW YORK, July 16 /PRNewswire-FirstCall/ — NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has entered into an advisory consulting agreement with Dr. Cai Jianqian, (Mrs Mao) of the Shandong Provincial Association of Chinese Medicine, to assist the company with its expansion into China and facilitate collaborations with prestigious hospitals in the Peoples Republic of China.
Ms. Cai Jianqian, a graduate of Shandong University of Traditional Chinese Medicine, has held the positions of Chief of the Administration of Chinese Medicine of Shandong Province, standing Council Member of the China Association of Chinese Medicine, Chairman of the Medicated Diet Association, Member of the lecturer team on Chinese acupuncture and moxibustion, and Corporate Representative of the Shandong Provincial Association of Chinese Medicine.
Ms. Cai held senior positions at China’s State Drug Administration and its predecessor for many years, was responsible for creating the development strategies and long-term and middle-term planning of the industry, and is considered by many to be instrumental in the continual improvement of the standards of medicine, education and research in the Chinese medicine industry. She was appointed in 1983 to head Chinese Medical Affairs of Shandong province, and during her tenure the number of Chinese medicine hospitals in Shandong province increased from eight to 150. In addition to being responsible for having established the Shandong Academy of Chinese Medicine and the Shandong Academy of Acupuncture and Moxibustion, she has been consistently praised by the Ministry of Health and the State Administration of Traditional Chinese Medicine for having made Shandong province one of the top ranked provinces in the PRC for Chinese medicine advancement.
A Council member of the American General Medical Association as well as a member of the editorial board of The Journal of American General Medicine, Ms. Cai is responsible for having established The Chinese Traditional Medicine Center in Chicago, two Chinese medicine hospitals in South Africa, twelve Chinese medicine outpatient clinics in Switzerland and the Chinese medicine rehabilitation centers in Poland and Russia. She has been extensively published in her field and is well regarded for her work in the research and development of new drugs, including the clinical study of complex diseases and acute illness, including cancer. She has been awarded an International MD and is certified by the International Open Traditional Medicine University & Institute of Medical Science of the United Nations, and the International Association of Traditional Medicine in Colombo in 1999.
Robin Smith, M.D., MBA, NeoStem’s Chief Executive Officer, said, “We are extremely pleased to welcome Ms. Cai to the NeoStem team and are confident that her extraordinary intellectual, administrative and political experience will guide the company as it expands abroad”. Ms. Cai stated, “I’m delighted to be affiliated with NeoStem Inc. This Company’s vision for collaborative medical innovation in the United States and China, especially in the field of stem cell research and applications using VSELs, opens enormous potential for both nations.”
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration.
For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company’s other periodic filings with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: email@example.com
SOURCE NeoStem, Inc.